Open access · CC-BY
via OpenAlex
Cell reprogramming for oligodendrocytes: A review of protocols and their applications to disease modeling and cell‐based remyelination therapies
Amy McCaughey‐Chapman, Bronwen Connor
Journal of Neuroscience Research · 2023 · ▲ 22 citations
Abstract
Oligodendrocytes are a type of glial cells that produce a lipid-rich membrane called myelin. Myelin assembles into a sheath and lines neuronal axons in the brain and spinal cord to insulate them. This not only increases the speed and efficiency of nerve signal transduction but also protects the axons from damage and degradation, which could trigger neuronal cell death. Demyelination, which is caused by a loss of myelin and oligodendrocytes, is a prominent feature of many neurological conditions, including Multiple sclerosis (MS), spinal cord injuries (SCI), and leukodystrophies. Demyelination is followed by a time of remyelination mediated by the recruitment of endogenous oligodendrocyte precursor cells, their migration to the injury site, and differentiation into myelin-producing oligodendrocytes. Unfortunately, endogenous remyelination is not sufficient to overcome demyelination, which explains why there are to date no regenerative-based treatments for MS, SCI, or leukodystrophies. To better understand the role of oligodendrocytes and develop cell-based remyelination therapies, human oligodendrocytes have been derived from somatic cells using cell reprogramming. This review will detail the different cell reprogramming methods that have been developed to generate human oligodendrocytes and their applications to disease modeling and cell-based remyelination therapies. Recent developments in the field have seen the derivation of brain organoids from pluripotent stem cells, and protocols have been devised to incorporate oligodendrocytes within the organoids, which will also be reviewed.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1002/jnr.25173
- Canonical
- link ↗
- Fetched
- 2026-09-13 MST
Cite this
APA
McCaughey‐Chapman, A., & Connor, B. (2023). Cell reprogramming for oligodendrocytes: A review of protocols and their applications to disease modeling and cell‐based remyelination therapies. <em>Journal of Neuroscience Research</em>. https://doi.org/10.1002/jnr.25173
Vancouver
McCaughey‐Chapman A, Connor B. Cell reprogramming for oligodendrocytes: A review of protocols and their applications to disease modeling and cell‐based remyelination therapies. Journal of Neuroscience Research. 2023. doi:10.1002/jnr.25173.
BibTeX
@article{amy2023Cellre,
title = {Cell reprogramming for oligodendrocytes: A review of protocols and their applications to disease modeling and cell‐based remyelination therapies},
author = {Amy McCaughey‐Chapman and Bronwen Connor},
journal = {Journal of Neuroscience Research},
year = {2023},
doi = {10.1002/jnr.25173},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Molecular Therapy 2025
Open access · CC-BY
Direct in vivo reprogramming to relieve tissue ischemia via induced vasculogenesis
Developmental Dynamics 2020
Open access · OA
Understanding embryonic development for cell‐based therapies of intervertebral disc degeneration: Toward an effort to treat disc degeneration subphenotypes
Frontiers in Genome Editing 2021
Open access · CC-BY
Non-immunogenic Induced Pluripotent Stem Cells, a Promising Way Forward for Allogenic Transplantations for Neurological Disorders
Journal of Clinical Investigation 2010
Open access · OA
Stem cells in human neurodegenerative disorders — time for clinical translation?
Cells 2023
Open access · CC-BY
Improving Efficiency of Direct Pro-Neural Reprogramming: Much-Needed Aid for Neuroregeneration in Spinal Cord Injury
Practical Diabetes 2003
Open access · OA